

Tuberculosis profile: Mozambique

Population 2019: 30 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	110 000 (68 000-162 000)	361 (223-532)
HIV-positive TB incidence	37 000 (23 000-55 000)	122 (75-180)
MDR/RR-TB incidence**	4 900 (2 500-8 000)	16 (8.3-26)
HIV-negative TB mortality	5 800 (3 100-9 300)	19 (10-31)
HIV-positive TB mortality	5 600 (3 300-8 600)	18 (11-28)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	3.7% (2.5-5.2)
Previously treated cases	13% (11-14)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	88% (59-140)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	11% (6-17)

TB case notifications, 2019

Total new and relapse	96 024
- % tested with rapid diagnostics at time of diagnosis	46%
- % with known HIV status	98%
- % pulmonary	94%
- % bacteriologically confirmed ^	37%
- % children aged 0-14 years	13%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	41%
- % men	46%
Total cases notified	97 111

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	31 864	34%
- on antiretroviral therapy	30 846	97%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	53%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB ^^	1 388
Patients started on treatment - MDR/RR-TB ^^	1 336
Laboratory-confirmed cases - XDR-TB ^^	97
Patients started on treatment - XDR-TB ^^	97
MDR/RR-TB cases tested for resistance to any fluoroquinolone	370

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	93%	90 947
Previously treated cases, excluding relapse, registered in 2018	89%	1 165
HIV-positive TB cases registered in 2018	89%	32 621
MDR/RR-TB cases started on second-line treatment in 2017	61%	825
XDR-TB cases started on second-line treatment in 2017	71%	24

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment



Treatment success rate



Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100-100)
---	-------------------

TB financing

National TB budget, 2020 (US\$ millions)	26
- Funding source, domestic	12%
- Funding source, international	88%
- unfunded	0%

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)